British Journal of Anaesthesia, 2003, Vol. 90, No. 3 304-308
© 2003 The Board of Management and Trustees of the British Journal of Anaesthesia
Clinical Investigations |
Comparison of ropivacaine 0.5% (in glucose 5%) with bupivacaine 0.5% (in glucose 8%) for spinal anaesthesia for elective surgery
1 University Department of Anaesthesia, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. 2 Present address: Department of Anaesthetics, St John’s Hospital, Livingston, West Lothian, UK
Corresponding author. E-mail: j.a.w.wildsmith@dundee.ac.uk 
This work was presented in abstract form at the European Society of Regional Anaesthesia meeting, Rome, September 20–23, 2000, and at the Anaesthetic Research Society, Newcastle, UK, March 29–30, 2001.
Background. Hyperbaric solutions of ropivacaine have been used successfully to provide spinal anaesthesia. This study was designed to compare the clinical efficacy of hyperbaric ropivacaine with that of the commercially available hyperbaric preparation of bupivacaine.
Methods. Forty ASA grade I–II patients undergoing lower-abdominal, perineal or lower-limb surgery under spinal anaesthesia were recruited and randomized to receive ropivacaine 5 mg ml–1 (with glucose 50 mg ml–1), 3 ml or bupivacaine 5 mg ml–1 (with glucose 80 mg ml–1), 3 ml. The level and duration of sensory block, intensity and duration of motor block, and time to mobilize and micturate were recorded. Patients were interviewed at 24 h and at 1 week to identify any residual problems.
Results. All blocks were adequate for the proposed surgery, but there were significant differences between the two groups in mean time to onset of sensory block at T10 (ropivacaine 5 min; bupivacaine 2 min; P<0.005), median maximum extent (ropivacaine T7; bupivacaine T5; P<0.005) and mean duration of sensory block at T10 (ropivacaine 56.5 min; bupivacaine 118 min; P=0.001). Patients receiving ropivacaine mobilized sooner (ropivacaine mean 253.5 min; bupivacaine 331 min; P=0.002) and passed urine sooner (ropivacaine mean 276 min; bupivacaine 340.5 min; P=0.01) than those receiving bupivacaine. More patients in the bupivacaine group required treatment for hypotension (>30% decrease in systolic pressure; P=0.001).
Conclusions. Ropivacaine 15 mg in glucose 50 mg ml–1 provides reliable spinal anaesthesia of shorter duration and with less hypotension than bupivacaine. The recovery profile for ropivacaine may be of interest given that more surgery is being performed in the day-case setting.
Br J Anaesth 2003; 90: 304–8
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. F. Luck, P. D. W. Fettes, and J. A. W. Wildsmith Spinal anaesthesia for elective surgery: a comparison of hyperbaric solutions of racemic bupivacaine, levobupivacaine, and ropivacaine Br. J. Anaesth., November 1, 2008; 101(5): 705 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Hansen, C. L. Beck, E. P. Beck, and R. W. Townsley Postarthroscopic Glenohumeral Chondrolysis Am. J. Sports Med., October 1, 2007; 35(10): 1628 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Y. Lee, W. D. Ngan Kee, H. K. Chang, C. L. So, and T. Gin Spinal Ropivacaine for Lower Limb Surgery: A Dose Response Study Anesth. Analg., August 1, 2007; 105(2): 520 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Camorcia, G. Capogna, C. Berritta, and M. O. Columb The Relative Potencies for Motor Block After Intrathecal Ropivacaine, Levobupivacaine, and Bupivacaine Anesth. Analg., April 1, 2007; 104(4): 904 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Subramani Laryngospasm during subarachnoid block Br. J. Anaesth., January 1, 2006; 96(1): 141 - 141. [Full Text] [PDF]
|
|
|
|
|
|
G. Cappelleri, G. Aldegheri, G. Danelli, C. Marchetti, M. Nuzzi, G. Iannandrea, and A. Casati Spinal Anesthesia with Hyperbaric Levobupivacaine and Ropivacaine for Outpatient Knee Arthroscopy: A Prospective, Randomized, Double-Blind Study Anesth. Analg., July 1, 2005; 101(1): 77 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Whiteside and J. Wildsmith Spinal anaesthesia: an update CEACCP, April 1, 2005; 5(2): 37 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. W. Fettes, G. Hocking, M. K. Peterson, J. F. Luck, and J. A. W. Wildsmith Comparison of plain and hyperbaric solutions of ropivacaine for spinal anaesthesia Br. J. Anaesth., January 1, 2005; 94(1): 107 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kokki, P. Ylonen, M. Laisalmi, M. Heikkinen, and M. Reinikainen Isobaric Ropivacaine 5 mg/mL for Spinal Anesthesia in Children Anesth. Analg., January 1, 2005; 100(1): 66 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kallio, E.-V. T. Snall, C. A. Tuomas, and P. H. Rosenberg Comparison of hyperbaric and plain ropivacaine 15 mg in spinal anaesthesia for lower limb surgery Br. J. Anaesth., November 1, 2004; 93(5): 664 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kallio, E.-V. T. Snall, M. P. Kero, and P. H. Rosenberg A Comparison of Intrathecal Plain Solutions Containing Ropivacaine 20 or 15 mg Versus Bupivacaine 10 mg Anesth. Analg., September 1, 2004; 99(3): 713 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Aveling, P. L. Klineberg, and J. A. W. Wildsmith Hyperbaric ropivacaine and bupivacaine Br. J. Anaesth., August 1, 2003; 91(2): 301 - 302. [Full Text] [PDF]
|
|